Does one voriconazole breakpoint suit all Candida species?

被引：6

作者：

Arendrup, Maiken Cavling

Denning, David W.

机构：

[1] Statens Serum Inst, Unit Mycol & Parasitol, DK-2300 Copenhagen, Denmark

[2] Univ Manchester, Manchester M23 9LT, Lancs, England

[3] Wythenshawe Hosp, Manchester M23 9LT, Lancs, England

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2007年 / 45卷 / 06期

关键词：

D O I：

10.1128/JCM.00412-07

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：2093 / 2093

页数：1

共 14 条

[1] In Vivo pathogenicity of eight medically relevant Candida species in an animal model
Arendrup, M
Horn, T
Frimodt-Moller, N
[J]. INFECTION, 2002, 30 (05) : 286 - 291
[2] Seminational surveillance of fungemia in Denmark: Notably high rates of fungemia and numbers of isolates with reduced azole susceptibility
Arendrup, MC
Fuursted, K
Gahrn-Hansen, B
Jensen, IM
Knudsen, JD
Lundgren, B
Schonheyder, HC
Tvede, M
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (09) : 4434 - 4440
[3] Adverse reactions to voriconazole
Boyd, AE
Modi, S
Howard, SJ
Moore, CB
Keevil, BG
Denning, DW
[J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (08) : 1241 - 1244
[4] Epidemiology of candidemia in Brazil:: a nationwide sentinel surveillance of candidemia in eleven medical Centers
Colombo, Arnaldo L.
Nucci, Marcio
Park, Benjamin J.
Nouer, Simone A.
Arthington-Skaggs, Beth
da Matta, Daniel A.
Warnock, David
Morgan, Juliette
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (08) : 2816 - 2823
[5] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, DW
Ribaud, P
Milpied, N
Caillot, D
Herbrecht, R
Thiel, E
Haas, A
Ruhnke, M
Lode, H
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : 563 - 571
[6] Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study
Diekema, DJ
Messer, SA
Brueggemann, AB
Coffman, SL
Doern, GV
Herwaldt, LA
Pfaller, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) : 1298 - 1302
[7] Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia
Krause, DS
Reinhardt, J
Vazquez, JA
Reboli, A
Goldstein, BP
Wible, M
Henkel, T
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2021 - 2024
[8] Safety of voriconazole and dose individualization
Lutsar, I
Hodges, MR
Tomaszewski, K
Troke, PF
Wood, ND
[J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) : 1087 - 1088
[9] Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte, J
Betts, R
Rotstein, C
Colombo, AL
Thompson-Moya, L
Smietana, J
Lupinacci, R
Sable, C
Kartsonis, N
Perfect, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) : 2020 - 2029
[10] Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality
Morrell, M
Fraser, VJ
Kollef, MH
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3640 - 3645

← 1 2 →